ID
IDYA.US Ideaya Biosciences Inc
- Market cap
- USD 3.08B
- P/E
- -
- P/B
- 2.82x
- ROE
- -41.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IDYA.US undervalued?
Graham numberThe Graham number of Ideaya Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ideaya Biosciences Inc fundamental analysis
No fundamental analysis for Ideaya Biosciences Inc yet.
Ideaya Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant setting…
Full company profileIdeaya Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ideaya Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 19.5M | 27.9M | 50.9M | 23.4M | 7.00M | 219M | 34.2M |
| Gross Profit | -391K | -886K | -1.25M | 19.5M | 27.9M | 50.9M | 19.4M | 3.17M | -96.0M | 34.2M |
| Operating Income | -14.4M | -36.4M | -44.3M | -35.3M | -50.3M | -62.5M | -134M | -327M | -159M | -491M |
| EBITDA | -11.5M | -33.5M | -43.0M | -34.0M | -48.5M | -60.4M | -109M | -271M | -155M | -475M |
| Net Income | -11.9M | -34.3M | -38.4M | -32.3M | -47.5M | -54.8M | -113M | -274M | -114M | -449M |
| EPS | -0.83 | -2.41 | -1.90 | -1.31 | -1.35 | -1.32 | -1.96 | -3.36 | -1.28 | -4.36 |
| Balance Sheet | ||||||||||
| Total Assets | 17.5M | 96.5M | 113M | 298M | 381M | 388M | 649M | 1.12B | 1.11B | 1.22B |
| Total Liabilities | 33.2M | 145M | 12.6M | 100.0M | 79.8M | 38.5M | 28.2M | 64.9M | 86.4M | 124M |
| Shareholders' Equity | -15.7M | -48.9M | 100M | 198M | 302M | 349M | 621M | 1.06B | 1.02B | 1.09B |
| Cash & Short-term Investments | 13.2M | 90.0M | 99.0M | 284M | 247M | 365M | 525M | 676M | 639M | 839M |
| Total Debt | 3.21M | - | 6.77M | 6.72M | 5.18M | 3.48M | 2.87M | 19.2M | 27.9M | 29.7M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -12.2M | -27.6M | -39.3M | 55.5M | -55.8M | -87.2M | -115M | -248M | -71.1M | -342M |
| Capital Expenditure | 1.76M | 1.71M | 1.35M | 493K | 2.64M | 3.44M | 2.37M | 3.86M | 2.37M | 2.81M |
| Free Cash Flow | -14.0M | -29.3M | -40.7M | 55.0M | -58.4M | -90.6M | -118M | -251M | -73.5M | -345M |
| Ratios | ||||||||||
| ROE | - | - | -38.3% | -16.3% | -15.8% | -15.7% | -18.2% | -25.9% | -11.1% | -41.1% |
| ROA | -67.9% | -35.6% | -34.0% | -10.8% | -12.5% | -14.1% | -17.4% | -24.4% | -10.2% | -36.9% |
| Net Profit Margin | - | - | - | -165.1% | -170.1% | -107.6% | -483.0% | -3,921.1% | -52.0% | -1,312.4% |
| Debt to Equity | - | - | 0.07x | 0.03x | 0.02x | 0.01x | 0.00x | 0.02x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ideaya Biosciences Inc dividends
Ideaya Biosciences Inc has not paid dividends in the last 9 fiscal years.
Who owns Ideaya Biosciences Inc
- Insiders 2.50%
- Institutions 97.50%
- Public & others 0.00%
- Shares outstanding 96.7M
- Free float 90.8M
Top funds holding IDYA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 5.20M | 5.38% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 4.73M | 4.89% | +0.36% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.13M | 3.23% | +5.09% | Sep 2026 |
| iShares Russell 2000 ETF | 2.29M | 2.37% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.70M | 1.76% | +2.69% | Oct 2026 |
| Fidelity Growth Company K6 | 1.35M | 1.40% | +0.41% | Aug 2026 |
| Fidelity Series Growth Company | 1.10M | 1.14% | -3.29% | Aug 2026 |
| Janus Henderson Triton D | 1.07M | 1.11% | 0.00% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 919K | 0.95% | +24.34% | Jun 2026 |
| Fidelity Small Cap Index | 918K | 0.95% | +0.15% | Aug 2026 |
| Federated Hermes Kaufmann R | 879K | 0.91% | 0.00% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 770K | 0.80% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 765K | 0.79% | 0.00% | Oct 2026 |
| Janus Global Life Science AUSD | 751K | 0.78% | +2.49% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 737K | 0.76% | +0.89% | Aug 2026 |
| T. Rowe Price Health Sciences | 727K | 0.75% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 707K | 0.73% | -0.19% | Oct 2026 |
| Janus Henderson Venture D | 675K | 0.70% | 0.00% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 663K | 0.69% | +12.87% | Apr 2026 |
| Fidelity Select Biotechnology | 638K | 0.66% | 0.00% | Aug 2026 |
Top institutions holding IDYA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 14.1M | 14.59% | +7.12% | Jun 2026 |
| BlackRock Inc | 8.89M | 9.20% | +5.34% | Jun 2026 |
| Jupiter Topco LLC | 8.58M | 8.87% | 0.00% | Jun 2026 |
| Capital Research Global Investors | 5.34M | 5.52% | -0.07% | Sep 2026 |
| Baker Bros Advisors LP | 5.01M | 5.18% | +26.95% | Jun 2026 |
| State Street Corp | 4.55M | 4.70% | +20.30% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.13M | 4.27% | +10.72% | Jun 2026 |
| Logos Global Management LP | 3.00M | 3.10% | -13.04% | Jun 2026 |
| Adage Capital Partners Gp LLC | 2.72M | 2.81% | -3.83% | Jun 2026 |
| Deerfield Management Co | 2.71M | 2.81% | +77.42% | Jun 2026 |
| Geode Capital Management, LLC | 2.43M | 2.51% | -3.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.21M | 2.28% | +67.76% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.93M | 2.00% | +3.82% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.73M | 1.78% | +3.89% | Sep 2026 |
| AllianceBernstein L.P. | 1.63M | 1.68% | +1,514.83% | Jun 2026 |
| Fiera Capital Corporation | 1.45M | 1.50% | -42.78% | Jun 2026 |
| Federated Hermes Inc | 1.43M | 1.48% | -52.07% | Jun 2026 |
| GSK PLC | 1.33M | 1.38% | 0.00% | Jun 2026 |
| BNP Paribas Investment Partners SA | 1.27M | 1.31% | +15.32% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.23M | 1.27% | -25.61% | Jun 2026 |
Ideaya Biosciences Inc company profile
- Company name
- Ideaya Biosciences Inc
- Ticker
- IDYA.US
- Exchange
- USA Stocks
- Listed since
- May 23, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Fiscal year end
- December
- Address
- 5000 Shoreline Court, South San Francisco, CA, United States, 94080
- Phone
- 650 443 6209
- Website
- ideayabio.com
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Ideaya Biosciences Inc management
10- Mr. Yujiro S. HataFounder, President, CEO & Chairman · born 1974
- Dr. Joshua Bleharski M.B.A., Ph.D.Chief Financial Officer · born 1975
- Mr. Andres Ruiz Briseno CPAChief Accounting Officer · born 1986
- Mr. Douglas B. SnyderChief Legal Officer · born 1964
- Dr. Michael A. White Ph.D.President of Research & Development · born 1965
- Dr. Darrin M. Beaupre M.D., Ph.D.Chief Medical Officer · born 1967
- Dr. Paul A. Barsanti Ph.D.Chief Technology Officer
- Ms. Francine ZelayaSenior VP & Head of Human Resources
- Mr. Mick O'QuigleySenior Vice President of Medical Writing & Project Management
- Mr. Daniel A. SimonChief Business Officer